RTOG-1122

Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or Without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma

Principal Investigator

Eudocia Quant Lee

Status

Disease Site

Brain [BN] Other

Phase

II

Developmental Therapeutics

No

Primary Objective

To assess the safety and tolerability of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1)

To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naïve patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2)

Data Collection Notice:

Data for this trial is being collected via the NRG/RTOG Data Center.

Safety Reports

Safety reports for NRG-RTOG 1122 can be found here.

Patient Population

Recurrent glioblastoma or variant (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma)

Target Accrual

127